Flash Finance

Panacea Biotec LimitedPANACEABIOCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹359.70
MCap ₹2,203 Cr
Panacea Biotec Limited — Stock analysis & AI research Panacea Biotec Limited — Multibagger AI analysis Panacea Biotec Limited — Seasonality — best & worst months Panacea Biotec Limited — Technical indicators & charts Panacea Biotec Limited — Technical setup — score, trend, support & resistance Panacea Biotec Limited — Live exchange announcements
📈 MACD Bullish Crossover📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹135 Cr
Sales · Jun 2026
+20.0% YoY
₹7 Cr
Operating Profit · Jun 2026
+341.7% YoY
5.4%
OPM % · Jun 2026
+300.0% YoY
₹1 Cr
Net Profit · Jun 2026
+120.7% YoY
₹0.23
EPS · Jun 2026
+121.1% YoY

📝 Panacea Biotec Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Panacea Biotec Limited reported revenue of ₹135 crore for the quarter ended June 2026 (Q1 FY27), up 20.0% from ₹112 crore in the same quarter last year, and up 21.2% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹1 crore from a net loss of ₹7 crore a year earlier. Earnings per share (EPS) came in at ₹0.23.

Operating profit stood at ₹7 crore — an operating margin (OPM) of 5.4%, compared with -2.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Panacea Biotec Limited posted revenue of ₹413 crore, a growth of 33.4% over FY25, with a net loss of ₹30 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹436 crore with a net loss of ₹22 crore.

Valuation snapshot

At the current price of ₹359.70, PANACEABIO has a market capitalisation of ₹2,203 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 21st-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.48%, foreign institutional investors (FIIs) 2.75%, domestic institutional investors (DIIs) 2.47%, public shareholders 22.30% of Panacea Biotec Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,203 Cr
Current Price ?
₹359.7
P/E ?
N/A
Industry P/E ?
37.20
P/B ?
7.73
P/S ?
5.05
P/FCF ?
N/A
Enterprise Value ?
₹2,468 Cr
EV/EBITDA ?
-329.97
PEG ?
N/A
Earnings Yield ?
-1.1%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹436 Cr
OPM ?
-1.7%
Profit after tax (TTM) ?
₹-22 Cr
EPS (TTM) ?
₹-3.56
ROCE ?
-3.0%
ROE ?
-7.6%
ROA ?
-2.6%
Growth
Sales — latest qtr ?
₹135 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
20.0%
YoY qtr profit growth ?
120.7%
Sales growth (3y) ?
17%
Sales growth (5y) ?
4%
Profit growth (3y) ?
19%
Profit growth (5y) ?
-21%
Financial Health
Debt ?
₹265 Cr
Debt to Equity ?
0.93
Interest Coverage ?
-1.4
Current Ratio ?
N/A
Ownership
Promoter holding ?
72.48%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-34.5%
Return 6 months ?
0.3%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 7275899595805777108681129199111135 +20.0% +21.2%
Operating Profit 1337107-9-10710-19-3-14-107 +341.7% +2333.3%
Other Income —1032316433654466 +22.4% +8.2%
Interest —33433344566767 +14.8% +8.8%
Depreciation —65555555555544 -6.3% +6.9%
Profit Before Tax 135131-1-15110-22-9-21-9-52 +122.6% +143.4%
Net Profit 13-20130-1-14110-12-7-16-7-01 +120.7% +872.2%
EPS 2.16-3.210.210.520.07-0.22-2.250.211.58-2.02-1.09-2.55-1.20-0.030.23 +121.1% +866.7%
OPM % 18.4% 4.6% 7.6% 10.5% 7.0% -11.5% -18.4% 8.8% 8.9% -27.3% -2.7% -15.1% -1.4% 0.3% 5.4% +300.0% +1700.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹310 Cr ₹413 Cr ₹436 Cr +33.4%
Operating Profit ₹-13 Cr ₹-18 Cr ₹-7 Cr -40.5%
OPM % -4.09% -4.30% -1.72% -5.1%
NPM % -4.92% -7.23% -5.00% -47.0%
Other Income ₹17 Cr ₹18 Cr ₹19 Cr +8.3%
Depreciation ₹20 Cr ₹19 Cr ₹18 Cr -7.6%
Interest ₹15 Cr ₹25 Cr ₹26 Cr +63.6%
EBIT ₹-33 Cr ₹-37 Cr ₹-26 Cr -10.9%
PBT ₹-26 Cr ₹-44 Cr ₹-33 Cr -68.3%
Tax — ₹-7 Cr ₹-7 Cr —
Net Profit ₹-15 Cr ₹-30 Cr ₹-22 Cr -96.2%
EPS ₹-2.48 ₹-4.87 ₹-3.55 -96.4%
Material Cost — ₹103 Cr ₹157 Cr —
Employee Cost — ₹52 Cr ₹75 Cr —
Extraordinary Items ₹0 Cr ₹0 Cr — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 6666 +0.0%
Reserves 320323308279 -9.4%
Borrowings 102125228265 +16.2%
Other Liabilities 296300327302 -7.6%
Total Liabilities 724754869852 -2.0%
Fixed Assets 435423416457 +9.9%
CWIP 289711991 -23.5%
Investments 0000 —
Other Assets 260234334303 -9.3%
Total Assets 724754869852 -2.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -113340 -100.0%
Cash from Investing Activity 2-47-610 +100.0%
Cash from Financing Activity 913900 -100.0%
Net Cash Flow 1-1330 -100.0%
Free Cash Flow -10-36-490 +100.0%
CFO/OP 15%247%-73%0% +100.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 17112527 +8.0%
Inventory Days 260278541218 -59.7%
Days Payable 289299586231 -60.6%
Cash Conversion Cycle -12-10-2115 +171.4%
Working Capital Days -135-79-141-8 +94.3%
ROCE % -13%4%-2%-3% -50.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 72.48%72.48%72.48%72.48%72.48%72.48% +0.0%
FIIs 0.79%1.06%1.36%1.60%2.31%2.75% +19.0%
DIIs 1.52%1.80%1.85%1.96%2.25%2.47% +9.8%
Public 25.20%24.65%24.31%23.96%22.96%22.30% -2.9%
No. of Shareholders 34,25633,59334,59732,62033,53232,961 -1.7%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Panacea Biotec Limited's revenue in Q1 FY27?
Panacea Biotec Limited reported revenue of ₹135 crore for the quarter ended June 2026 (Q1 FY27), up 20.0% from ₹112 crore in the same quarter last year, and up 21.2% sequentially over the March 2026 quarter.
What was Panacea Biotec Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹1 crore from a net loss of ₹7 crore a year earlier. Earnings per share (EPS) came in at ₹0.23.
What is PANACEABIO's market capitalisation and P/E ratio?
At the current price of ₹359.70, PANACEABIO has a market capitalisation of ₹2,203 crore.
Who owns Panacea Biotec Limited? (shareholding pattern)
As of Sep 2026, promoters held 72.48%, foreign institutional investors (FIIs) 2.75%, domestic institutional investors (DIIs) 2.47%, public shareholders 22.30% of Panacea Biotec Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI